Atorvastatin PO, NG
1 tablet 10mg
Secondary prevention in patients with coronary artery disease
Treatment of hypercholesterolaemia
PO / NG:
10mg, 20mg, 40mg and 80mg strengths (white). Tablets may be crushed for administration via NG tube.
Commence at 10-20mg daily at night; slowly increase to a maximum of 80mg if required.
0.2mg/kg daily, increased every 4 weeks to a maximum of 1.6mg/kg daily.
DOSAGE IN RENAL FAILURE AND RENAL REPLACEMENT THERAPY
Dose as in normal renal function
Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase. Atorvastatin is rapidly absorbed after oral administration; maximum plasma concentrations occur within 1-2 hours. It can be taken with or without food.
Active liver disease or unexplained persistent elevations of serum transaminases.
Hypersensitivity to any component of this medication.
HMG-CoA reductase inhibitors, like some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function.
Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with atorvastatin and with other drugs in this class.
Patients should be advised to report promptly unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.
CK should be measured if there is concern about development of myopathy due to statins.
Drug/Laboratory Test Interactions
The risk of myopathy during treatment with other drugs of this class is increased with concurrent administration of cyclosporin, fibric acid derivatives, niacin (nicotinic acid), erythromycin, and azole antifungals
When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%. Patients taking digoxin should be monitored appropriately.
Body as a Whole:
Constipation, derangement of LFTs, flatulence, dyspepsia, and abdominal pain
Insomnia, dizziness, paraesthesia, somnolence